54,741 Illumina, Inc. $ILMN Shares Acquired by International Assets Investment Management LLC

Key Points

• International Assets Investment Management LLC increased its Illumina stake by 10,608.7%, acquiring 54,741 additional shares and ending the quarter with 55,257 shares worth approximately $15.1 million. Institutional investors collectively own 89.42% of the company.
• Illumina reported quarterly EPS of $1.62, beating the $1.36 consensus estimate, while revenue rose 4.2% year over year to $1.17 billion. However, the stock was down 18.6%, pressured by concerns over China exposure, tariffs, weaker research-market demand and business mix.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $238.53. Insiders have sold more than 2 million shares worth approximately $436.4 million over the past 90 days.

International Assets Investment Management LLC increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 10,608.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 55,257 shares of the life sciences company's stock after acquiring an additional 54,741 shares during the quarter. International Assets Investment Management LLC's holdings in Illumina were worth $15,123,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. bought a new position in Illumina in the 2nd quarter worth about $3,374,423,000. Plato Investment Management Ltd bought a new stake in shares of Illumina during the second quarter valued at approximately $948,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Illumina during the second quarter valued at approximately $30,501,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Illumina during the second quarter valued at approximately $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new position in shares of Illumina during the second quarter worth approximately $6,711,000. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Stock Down 18.6%

ILMN stock opened at $235.99 on Friday. The firm has a market cap of $35.63 billion, a PE ratio of 40.62, a P/E/G ratio of 3.34 and a beta of 1.41. Illumina, Inc. has a 12 month low of $106.12 and a 12 month high of $309.35. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm has a 50 day simple moving average of $249.30 and a 200 day simple moving average of $176.18.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.26. The firm had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 29.41%. The firm's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.34 earnings per share. Equities research analysts forecast that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In other news, Director Keith Meister sold 119,501 shares of the company's stock in a transaction on Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the sale, the director directly owned 770,350 shares of the company's stock, valued at $168,244,440. This represents a 13.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Christensen Wedel sold 1,033 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares of the company's stock, valued at $2,685,684.96. This trade represents a 6.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 2,061,235 shares of company stock valued at $436,356,102. 2.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ILMN shares. Piper Sandler increased their price objective on Illumina from $225.00 to $305.00 and gave the stock an "overweight" rating in a report on Monday, September 28th. Barclays lifted their target price on Illumina from $160.00 to $200.00 and gave the company an "underweight" rating in a research note on Wednesday, October 7th. Zacks Research downgraded Illumina from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 1st. Royal Bank Of Canada boosted their price target on Illumina from $230.00 to $310.00 and gave the stock an "outperform" rating in a research report on Monday, October 5th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Illumina in a research note on Monday, August 31st. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the company's stock. According to data from MarketBeat, Illumina has a consensus rating of "Hold" and an average target price of $238.53.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.